The results revealed that in breast cancer PDOs, HER-2 and estrogen receptor (ER) exhibited strong immunoreactivity, whereas progesterone receptor (PR) expression was lower, consistent with the phenotype of primary breast cancer (Figure 2a). Here, ERBB2 is linked to breast cancer.